1
|
Tsivgoulis G, Kargiotis O, Rudolf J, Komnos A, Tavernarakis A, Karapanayiotides T, Ellul J, Katsanos AH, Giannopoulos S, Gryllia M, Safouris A, Papamichalis P, Vadikolias K, Mitsias P, Hadjigeorgiou G. Intravenous thrombolysis for acute ischemic stroke in Greece: the Safe Implementation of Thrombolysis in Stroke registry 15-year experience. Ther Adv Neurol Disord 2018; 11:1756286418783578. [PMID: 30034535 PMCID: PMC6048606 DOI: 10.1177/1756286418783578] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Accepted: 01/06/2018] [Indexed: 01/08/2023] Open
Abstract
Background: Intravenous thrombolysis (IVT) remains the only approved systemic reperfusion
treatment for acute ischemic stroke (AIS), however there are scarce data
regarding outcomes and complications of IVT in Greece. We evaluated safety
and efficacy outcomes of IVT for AIS in Greece using the Safe Implementation
of Thrombolysis in Stroke: International Stroke Thrombolysis Register
(SITS-ISTR) dataset. Methods: All AIS patients treated with IVT in Greece between December 2002 and July
2017 and recorded in the SITS-ISTR were evaluated. Demographics, risk
factors, baseline stroke severity [defined using National Institutes of
Health Stroke Scale (NIHSS)], and onset-to-treatment time (OTT) were
recorded. Safety outcomes included symptomatic intracranial hemorrhage
(sICH) and 3-month mortality rates. The efficacy outcomes evaluated a
reduction in baseline NIHSS score at 2 and 24 h following IVT onset, 3-month
favorable functional outcome [FFO; modified Rankin scale (mRS) scores of
0–1] and 3-month functional independence (FI; mRS-scores of 0–2). The safety
and efficacy outcomes were assessed comparatively with previously published
data from SITS national and international registries. Results: A total of 523 AIS patients were treated with IVT in 12 Greek centers
participating in the SITS-ISTR during the study period (mean age 62.4 ±
12.7; 34.6% women; median baseline NIHSS score: 11 points; median OTT: 150
min). The rates of sICH were 1.4%, 2.3%, and 3.8% according to the
SIST-MOST, ECASS II, and NINDS criteria respectively. The median reduction
in NIHSS score at 2 and 24 h was 3 [interquartile range (IQR): 1–5] and 5
(IQR: 2–8) points respectively. The 3-month FI, FFO and mortality were
66.5%, 55.6% and 7.9%. All safety and efficacy outcomes were comparable with
available data from SITS-ISTR in other European countries. Conclusions: Our study underscores the safety and efficacy of IVT for AIS in Greece.
Additional action is necessary in order to increase the availability of IVT
in the Greek population and to include more centers in the SITS-ISTR.
Collapse
Affiliation(s)
- Georgios Tsivgoulis
- Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece
| | | | - Jobst Rudolf
- Department of Neurology, Papageorgiou Hospital, Thessaloniki, Greece
| | | | | | - Theodoros Karapanayiotides
- Second Department of Neurology, AHEPA University Hospital, Aristotle University of Thessaloniki, School of Medicine, Thessaloniki, Greece
| | - John Ellul
- Department of Neurology, University Hospital of Patras, School of Medicine, University of Patras, Patras, Greece
| | - Aristeidis H Katsanos
- Department of Neurology, University of Tennessee Health Science Center, Memphis, Tennessee, USA
| | - Sotirios Giannopoulos
- Department of Neurology, University of Ioannina School of Medicine, Ioannina, Greece
| | - Maria Gryllia
- Department of Neurology, Athens General Hospital G. Gennimatas, Athens, Greece
| | - Apostolos Safouris
- Second Department of Neurology, Attikon University Hospital, National and Kapodistrian University of Athens, Athens, Greece Stroke Unit, Metropolitan Hospital, Piraeus, Greece
| | | | - Konstantinos Vadikolias
- Department of Neurology, Democritus University of Thrace, School of Medicine, Alexandroupolis, Greece
| | - Panayiotis Mitsias
- Department of Neurology Medical School, University of Crete, Heraklion, Crete, Greece
| | | |
Collapse
|
2
|
Brown MD, Burton JH, Nazarian DJ, Promes SB. Clinical Policy: Use of Intravenous Tissue Plasminogen Activator for the Management of Acute Ischemic Stroke in the Emergency Department. Ann Emerg Med 2016; 66:322-333.e31. [PMID: 26304253 DOI: 10.1016/j.annemergmed.2015.06.031] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
3
|
Sharma VK, Kawnayn G, Sarkar N. Acute ischemic stroke: comparison of low-dose and standard-dose regimes of tissue plasminogen activator. Expert Rev Neurother 2014; 13:895-902. [PMID: 23965163 DOI: 10.1586/14737175.2013.827412] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Intravenous tissue plasminogen activator (IV-TPA), administered within 4.5 h of symptom onset, is the only therapeutic agent approved for achieving arterial recanalization in acute ischemic stroke. Current major guidelines recommend the use of a standard dose (0.9 mg/kg bodyweight; maximum 90 mg) of IV-TPA. However, comparable efficacy of IV-TPA was demonstrated in the observational studies from Japan when a lower dose (0.6 mg/kg bodyweight; maximum 60 mg) was used and later approved by the regulatory authorities. Although limited in numbers, considerable variations in the dose of IV-TPA are noted in recent publications from Asia, with variable results and optimal dose of TPA in Asia remains controversial. The authors present a systemic review of the existing literature and compare the efficacy and safety of standard-versus the low-dose IV-TPA therapy in acute ischemic stroke.
Collapse
Affiliation(s)
- Vijay K Sharma
- Division of Neurology, Department of Medicine, National University Hospital, 5 Lower Kent Ridge Road, 119074 Singapore
| | | | | |
Collapse
|
4
|
Ferrari J, Knoflach M, Seyfang L, Lang W. Differences in process management and in-hospital delays in treatment with iv thrombolysis. PLoS One 2013; 8:e75378. [PMID: 24069406 PMCID: PMC3771907 DOI: 10.1371/journal.pone.0075378] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2013] [Accepted: 08/13/2013] [Indexed: 11/19/2022] Open
Abstract
OBJECTIVES Rapid initiation of intravenous thrombolysis improves patient's outcome in acute stroke. We analyzed inter-center variability and factors that influence the door-to-needle time with a special focus on process measurements in all Austrian stroke units. METHODS Case level data of patients receiving intravenous thrombolysis in the Austrian Stroke Unit Registry were enriched with information of a structured questionnaire on center specific process measures of all Austrian stroke units. Influence of case and center specific variables was determined by LASSO procedure. RESULTS Center specific median door-to-needle time ranged between 30 and 78 minutes. Between April 2004 and November 2012, 6246 of 57991 patients treated in Austrian stroke units with acute ischemic stroke received intravenous thrombolysis. An onset-to-door time >120 minutes, patients with total anterior circulation stroke, recent year of admission, patient transportation with ambulance crew and emergency physician, the use of point of care tests reduced the door-to-needle time, whereas onset-to-door ≤ 60 minutes, unknown onset-to-door, patients with an NIHSS ≤ 4 or posterior circulation stroke, initial admission to a general emergency department, a distant radiology department, primary imaging modality other than plain CT and waiting for the lab results were associated with an increase in door-to-needle time. Case level and center specific factors could explain the inter center variability of door-to-needle times in 31 of 34 stroke units in Austria. CONCLUSIONS In light of our results it seems crucial that every single stroke center documents and critically reviews possibilities of optimizing practice strategies in acute stroke care.
Collapse
Affiliation(s)
- Julia Ferrari
- Department of Neurology, Hospital Barmherzige Brueder, Vienna, Austria
| | - Michael Knoflach
- Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
| | - Leonhard Seyfang
- Department for Clinical Neurosciences and Preventive Medicine, Danube University, Krems, Austria
| | - Wilfried Lang
- Department of Neurology, Hospital Barmherzige Brueder, Vienna, Austria
| |
Collapse
|
5
|
Sanelli PC, Sykes JB, Ford AL, Lee JM, Vo KD, Hallam DK. Imaging and treatment of patients with acute stroke: an evidence-based review. AJNR Am J Neuroradiol 2013; 35:1045-51. [PMID: 23598836 DOI: 10.3174/ajnr.a3518] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
Evidence-based medicine has emerged as a valuable tool to guide clinical decision-making, by summarizing the best possible evidence for both diagnostic and treatment strategies. Imaging plays a critical role in the evaluation and treatment of patients with acute ischemic stroke, especially those who are being considered for thrombolytic or endovascular therapy. Time from stroke-symptom onset to treatment is a strong predictor of long-term functional outcome after stroke. Therefore, imaging and treatment decisions must occur rapidly in this setting, while minimizing unnecessary delays in treatment. The aim of this review was to summarize the best available evidence for the diagnostic and therapeutic management of patients with acute ischemic stroke.
Collapse
Affiliation(s)
- P C Sanelli
- From the Departments of Radiology (P.C.S., J.B.S.)Public Health (P.C.S.), Weill Cornell Medical Center/NewYork-Presbyterian Hospital, New York, New York
| | - J B Sykes
- From the Departments of Radiology (P.C.S., J.B.S.)
| | - A L Ford
- Departments of Neurology (A.L.F., J.-M.L.)
| | - J-M Lee
- Departments of Neurology (A.L.F., J.-M.L.)Radiology (J.-M.L., K.D.V.), Washington University, School of Medicine, St. Louis, Missouri
| | - K D Vo
- Radiology (J.-M.L., K.D.V.), Washington University, School of Medicine, St. Louis, Missouri
| | - D K Hallam
- Department of Radiology (D.K.H.), University of Washington Medical Center, Seattle, Washington
| |
Collapse
|
7
|
Intravenous thrombolysis in acute ischemic stroke after POLKARD: one center analysis of program impact on clinical practice. Adv Med Sci 2012; 56:231-40. [PMID: 22112428 DOI: 10.2478/v10039-011-0045-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
PURPOSE Intravenous thrombolysis in the acute ischemic stroke was initiated in Poland within the National Cardiovascular Disease Prevention and Treatment Program POLKARD in the years 2003-2008. Since 2009 the procedure has been reimbursed by the National Health Fund (Narodowy Fundusz Zdrowia - NFZ). The purpose of the presented study was to assess whether the change of financing institution was associated with the change in proportion of patients treated and with any of the clinical parameters or stroke outcomes. PATIENTS AND METHODS We reviewed the data of the 90 consecutive patients with acute ischemic stroke treated with intravenous thrombolysis within 3-hours from symptoms onset. The differences between the POLKARD period and the year 2009, regarding clinical parameters, time delays, death rates and functional outcomes on day 90 after the stroke were analyzed. The association of outcome measures with baseline characteristics of the patients was analyzed with binary logistic regression. RESULTS In 2009 there was a significant increase in the proportion of patients treated (7.6%, 95%CI 5.3-10.7%, vs. 4.3%, 95%CI 3.3-5.5% respectively, p=0.013). There were no differences in age, baseline neurological presentation, prevalence of stoke risk factors, treatment time delays or hemorrhagic complications. Higher, but not significantly, 90-day mortality was observed (32.1%, 95%CI 13.3-54.1% vs. 16.1%, 95%CI 6.4-29.7% respectively, p=0.101). Baseline neurological deficits and in-hospital treatment time delays were significant predictors of disability and death. CONCLUSIONS After the Polish Ministry of Health program POLKARD termination and elimination of the reimbursement limits, higher proportion of ischemic stroke patients could be treated with the intravenous thrombolysis.
Collapse
|